Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial

Lilly added pegilodecakin to its portfolio with the acquisition of Armo BioSciences last year. Credit: Momoneymoproblemz.



  • Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial